Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab dosing algorithms in diabetic macular edema (DI vs PRN)
2014-002854-37Phase 4Terminated
- Sponsor
- Novartis
- Start
- Oct 2014
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial in diabetic macular edema (DME) and diabetic retinopathy (DR) comparing Investigator discretion (DI) ranibizumab dosing with PRN standard-of-care ranibizumab dosing (2 arms). Started Oct 2014; status: terminated.
02
Drugs
ranibizumab
03
Conditions
diabetic macular edema (DME)diabetic retinopathy (DR)
Beyond the preview
Go deeper on 2014-002854-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002854-37.